PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer.

摘要: Over the last decade, use of targeted therapies has immensely increased in treatment cancer. However, for endometrial carcinomas (ECs) lagged behind, although potential molecular markers have been identified. This is particularly problematic type II ECs, since these aggressive tumors are usually not responsive toward current standard therapies. Therefore, ECs responsible most EC-related deaths, indicating need new options. Interestingly, analyses uncovered frequent genetic alterations (up to 40%) PPP2R1A, encoding Aα subunit tumor suppressive heterotrimeric protein phosphatase 2A (PP2A). PPP2R1A mutations were also reported I and other common gynecologic cancers, albeit at much lower frequencies (0-7%). Nevertheless, PP2A inactivation latter cancer types via mechanisms, particular by expression Cancerous Inhibitor (CIP2A) Methylesterase-1 (PME-1) proteins. In this review, we discuss therapeutic direct indirect targeting compounds, possibly combination with anti-cancer drugs, EC. Furthermore, investigate status as a predictive and/or prognostic marker ECs.